Streetbeat News

ENTA

Enanta Pharmaceuticals, Inc.

https://www.enanta.com

Industry

Biotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Open

11.27

Mkt cap

235M

Volume

58K

High

11.29

P/E Ratio

-2.03

52-wk high

17.80

Low

11.01

Div yield

N/A

52-wk low

8.08

JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on Enanta Pharma (NASDAQ:ENTA) but lowers the price target from $23 to $22.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 3:34 pm

Enanta Pharma (NASDAQ:ENTA) reported Q2 2024 earnings with a GAAP EPS of $(1.47), missing the $(1.33) estimate by 10.53%, and sales of $17.054M, beating the $16.522M estimate by 3.22%. This represents a 17.88% improvement in EPS and a 4.16% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 8:05 pm

JP Morgan analyst Eric Joseph has maintained an Underweight rating on Enanta Pharma (NASDAQ: ENTA) and lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:43 pm

Enanta Pharma (NASDAQ:ENTA) reported Q1 earnings with an EPS of $-1.58, missing estimates by 32.77% against an expected $-1.19. Revenue decreased by $5.58 million from the previous year. Despite a positive performance in the last quarter leading to an 11.52% share price increase, this quarter's results fell short of expectations.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 9:15 pm

Enanta Pharma (NASDAQ:ENTA) reported Q1 2024 earnings with a GAAP EPS of $(1.58), missing the $(1.23) estimate, and sales of $18.00M, missing the $21.95M estimate. This represents a decrease in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 9:14 pm

Numerous companies are scheduled to report their earnings on February 7, 2024, covering a wide range of industries from technology to healthcare. Notable mentions include Madison Square Garden, Scotts Miracle Gro, TotalEnergies, Equinor, Euronet Worldwide, Flex LNG, Alibaba Group Holding, and many others. The earnings reports are expected to provide insights into the companies' financial health and market performance.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 10:13 am

Enanta Pharma (NASDAQ:ENTA) is scheduled to release its quarterly earnings report on February 7, 2024, with analysts expecting an EPS of $-1.19. Historical data shows that the company's stock price reacts more significantly to guidance than to earnings beats or misses. Last quarter, ENTA beat the EPS estimate, resulting in an 11.52% stock price increase the following day. However, over the last year, ENTA's shares have declined by 75.66%, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

February 06, 2024 | 6:02 pm

Enanta Pharmaceuticals announced its plans for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference, including an update on its pipeline. The company is expanding into immunology with a new oral KIT inhibitor program for CSU, aiming for development candidate selection in 2024. Enanta also expects topline data from a Phase 2 study of Zelicapavir (EDP-938) for RSV treatment in 3Q 2024, and challenge study data for EDP-323, another RSV treatment, in the same quarter.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 12:07 pm

Oppenheimer analyst Jay Olson has maintained a Perform rating on Enanta Pharma (NASDAQ: ENTA) but has reduced the price target from $25 to $21.

Portfolio Pulse from Benzinga Newsdesk

November 22, 2023 | 6:47 pm

Enanta Pharmaceuticals' stock is trading higher following the announcement of their Q4 revenue results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

November 21, 2023 | 5:24 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.